Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Report 2026

Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Report 2026 Market Overview

• Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Report 2026 market size has reached to $5.09 billion in 2025 • Expected to grow to $9.98 billion in 2030 at a compound annual growth rate (CAGR) of 14.3% • Growth Driver: Surge In Alzheimer’s Disease Fueling The Growth Of The Market Due To Rising Aging Population And Increasing Disease Prevalence • Market Trend: FDA Approval Of First Non-Antipsychotic Therapy Expands Treatment Options For Alzheimer’s-Related Agitation • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market?

Alzheimer’s agitation non-antipsychotic drug therapy refers to pharmacological approaches used to manage agitation, aggression, and related behavioral symptoms in individuals with Alzheimer's disease without relying on antipsychotic medications. These therapies focus on modulating neurotransmitter activity and neurobiological pathways involved in mood, behavior, and cognitive regulation to improve symptom control. Alzheimer’s agitation non-antipsychotic drug therapies are designed to provide safer alternatives to antipsychotics by reducing associated risks such as sedation, cognitive decline, and cardiovascular side effects. The main drug classes of alzheimer's agitation non-antipsychotic drug therapy include N methyl D aspartate receptor antagonists, sigma one receptor agonists, serotonin modulators, and novel central nervous system targets. N methyl D aspartate receptor antagonists refer to therapeutic agents that regulate glutamate activity in the brain to help manage agitation symptoms associated with Alzheimer's disease. These therapies are designed for patient settings including memory care facilities, home care, assisted living, and hospital inpatient settings and address disease stages such as mild to moderate Alzheimer's, and moderate to severe Alzheimer's. They are administered through routes including oral, injectable, transdermal, and intranasal and are utilized by end users including hospitals, neurology clinics, geriatric care centers, rehabilitation centers, and home healthcare providers.

What Is The Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Growth Forecast?

The alzheimer's agitation non-antipsychotic drug therapy market size is expected to see rapid growth in the next few years. It will grow to $9.98 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to growing investments in neurodegenerative disease drug development, increasing demand for precision medicine approaches, rising clinical research for novel neurobehavioral therapies, expansion of home based dementia care services, increasing regulatory support for safer treatment alternatives. Major trends in the forecast period include increasing development of safer alternatives to antipsychotic therapies, growing focus on targeted neurobehavioral symptom management, rising adoption of multimodal therapeutic approaches for agitation treatment, increasing research on neurotransmitter pathway modulation therapies, expansion of clinical trials for novel central nervous system therapies.

What Are The Drivers Of The Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market?

The rising prevalence of Alzheimer's disease is expected to propel the growth of the Alzheimer's agitation non-antipsychotic drug therapy market going forward. Alzheimer’s disease refers to a progressive neurodegenerative disorder that gradually impairs memory, thinking, and behavior due to brain cell damage and loss. The rising prevalence of Alzheimer’s disease is driven by increasing life expectancy, as a larger aging population leads to a higher number of individuals reaching the age groups most at risk for developing the condition. Alzheimer’s agitation non-antipsychotic drug therapy helps address the behavioral and psychological symptoms associated with Alzheimer's disease, improving patient management and quality of life, which supports better long-term care outcomes for the growing patient population. For instance, in December 2025, according to the Australian Government, an Australian-based government department, about 25,000 people in Australia were living with dementia, including nearly 266,000 women and 159,000 men, representing roughly 16 cases per 1,000 Australians (19 per 1,000 women and 12 per 1,000 men). Therefore, the rising prevalence of Alzheimer's disease is driving the growth of the Alzheimer's agitation non-antipsychotic drug therapy industry. The expanding research and development investments are expected to propel the growth of the Alzheimer's agitation non-antipsychotic drug therapy market going forward. Research and development investments refer to the financial resources allocated by governments, pharmaceutical companies, and academic institutions toward discovering, developing, and clinically testing new therapeutic solutions. The growing scale of R&D investment is primarily driven by the increasing global burden of Alzheimer's disease, as a rising aging population expands the pool of patients requiring targeted interventions, thereby intensifying the urgency for effective non-antipsychotic treatment options. Greater R&D funding accelerates the discovery and clinical validation of novel non-antipsychotic compounds that directly address agitation symptoms in Alzheimer's patients, expanding the therapeutic pipeline and bringing more treatment options to market. For instance, in February 2025, according to the National Center for Science and Engineering Statistics (NCSES), a US-based government statistical agency, U.S. research and development expenditures rose from $892 billion in 2022 to $940 billion in 2023, reflecting an increase of $48 billion. Therefore, expanding research and development investments are driving the growth of the Alzheimer's agitation non-antipsychotic drug therapy industry.

Key Players In The Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market

Major companies operating in the alzheimer's agitation non-antipsychotic drug therapy market report are Axsome Therapeutics Inc., Bristol Myers Squibb Company, Suven Life Sciences Limited, IGC Pharma Inc., Exciva GmbH, Neumora Therapeutics Inc.

Global Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Trends and Insights

Major companies operating in the Alzheimer's agitation non-antipsychotic drug therapy market are focusing on developing innovative non-antipsychotic treatments to address agitation symptoms associated with Alzheimer's disease while minimizing the safety concerns linked to traditional antipsychotic medications. Non-antipsychotic therapies refer to treatments that manage agitation through alternative neurological pathways without relying on antipsychotic mechanisms, potentially offering improved safety and tolerability for elderly patients. For instance, in April 2026, Axsome Therapeutics, a US-based biopharmaceutical company, received U.S. FDA approval for Auvelity (dextromethorphan-bupropion) for the treatment of agitation associated with dementia due to Alzheimer's disease. The approval introduced the first FDA-approved non-antipsychotic treatment for this indication, offering a new approach to managing agitation symptoms. It targets NMDA and sigma-1 receptors, expanding treatment options for patients and caregivers.

What Defines the Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market?

The alzheimer’s agitation non-antipsychotic drug therapy market consists of sales of mirtazapine, gabapentin, pregabalin, suvorexant, ramelteon, and melatonin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Report 2026?

The alzheimer's agitation non-antipsychotic drug therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the alzheimer's agitation non-antipsychotic drug therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.